Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH
Portfolio Pulse from Vandana Singh
Lexaria Bioscience Corp (NASDAQ:LEXX) has completed its animal study HOR-A22-1, showing significant enhancement in the oral delivery of estrogen hormone estradiol using its DehydraTECH technology. The DehydraTECH-estradiol formulation achieved a 900% higher average peak concentration in the bloodstream compared to the control formulation.
May 18, 2023 | 6:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexaria Bioscience's DehydraTECH technology has shown significant improvement in oral delivery of estrogen hormone estradiol in an animal study, potentially boosting the company's product offerings.
The successful completion of the animal study demonstrates the effectiveness of Lexaria Bioscience's DehydraTECH technology in enhancing the oral delivery of estradiol. This could lead to increased demand for the company's products and services, positively impacting its stock price in the short term. The stock price has already increased by 13.70% at $0.84 on the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100